Table 1.
Baseline demographic and clinical characteristics of survey respondents and non-respondents; completers and non-completers
| Measure | Invited for survey participation (n=4,000)
|
Survey respondents (n=1,159)
|
||||
|---|---|---|---|---|---|---|
| Survey respondents | Survey non-respondents | P-valuea | Survey completers | Survey non-completers | P-valuea | |
| n (%) | 1,159 (29.0) | 2,841 (71.0) | n/a | 765 (66.0) | 394 (34.0) | n/a |
| Age, years (mean [SD]) | 72.2 (8.5) | 72.0 (9.5) | 0.640 | 72.0 (8.3) | 72.7 (9.0) | 0.180 |
| Age ≥65 years (n [%]) | 985 (85.0) | 2,333 (82.1) | 0.029 | 650 (85.0) | 335 (85.0) | 0.979 |
| Sex, female (n [%]) | 630 (54.4) | 1,513 (53.3) | 0.526 | 411 (53.7) | 219 (55.6) | 0.547 |
| Race/ethnicity, white (n [%]) | 1,035 (89.3) | 2,437 (85.8) | 0.024 | 698 (91.2) | 337 (85.5) | 0.031 |
| Geographic region, south (n [%]) | 694 (59.9) | 1,931 (68.0) | <0.001 | 443 (57.9) | 251 (63.7) | 0.043 |
| Qualify for low-income subsidy and dual eligible (n [%]) | 172 (14.8) | 462 (16.3) | 0.264 | 102 (13.3) | 70 (17.8) | 0.044 |
| RxRisk-V comorbidity index | 5.7 (3.7) | 6.0 (3.8) | 0.014 | 5.6 (3.8) | 6.0 (3.7) | 0.033 |
| Deyo–Charlson comorbidity index | 2.0 (1.9) | 2.1 (1.9) | 0.135 | 1.9 (1.8) | 2.0 (1.9) | 0.877 |
| Comorbidities (top five)b | ||||||
| Unspecified essential hypertension (ICD-9-CM: 401.9x) n (%) | 722 (62.3) | 1,851 (65.2) | 0.087 | 465 (60.8) | 257 (65.2) | 0.139 |
| Other and unspecified hyperlipidemia (ICD-9-CM: 272.4x) n (%) | 671 (57.9) | 1,639 (57.7) | 0.906 | 453 (59.2) | 218 (55.3) | 0.204 |
| Essential hypertension, benign (ICD-9-CM: 401.1x) n (%) | 425 (36.7) | 1,132 (39.9) | 0.062 | 282 (36.9) | 143 (36.3) | 0.849 |
| Dyspnea and respiratory abnormalities (ICD-9-CM: 786.0x) n (%) | 443 (38.2) | 1,038 (36.5) | 0.316 | 286 (37.4) | 157 (39.9) | 0.414 |
| Diabetes mellitus without mention of complication (ICD-9-CM: 250.0x) n (%) | 364 (31.4) | 1,034 (36.4) | 0.003 | 238 (31.1) | 126 (32.0) | 0.763 |
| CAT score (mean [SD]) | n/a | n/a | n/a | 17.6 (9.7) | 17.2 (10.6) | 0.480 |
Notes:
a
Two-sample t-test used for continuous measures; chi-square test used for categorical measures (all tests are two-sided);
b
top five comorbidities based on 4,000 COPD members invited for survey participation, at the four digit ICD-9-CM level.
Abbreviations: CAT, COPD assessment test; ICD-9-CM, International Classification of Diseases-9th edition; SD, standard deviation; n/a, not applicable.